Track Eledon Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eledon Pharmaceuticals, Inc. ELDN · Stock Open Eledon Pharmaceuticals, Inc. in new tab

2.12 USD
EPS
-0.90
P/B
3.00
ROE
-110.71
Beta
0.96
Target Price
9.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 18, 2027
EPS-0.90
Book Value0.89
Price to Book3.00
Debt/Equity0.65
% Insiders0.329%
Estimates
Forward P/E-3.47
Forward EPS-0.77
Target Mean Price9.00

DCF valuation

Model fair value for Eledon Pharmaceuticals, Inc. (ELDN)
Result
Sign in to run the valuation for ELDN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus None · mean target 9.00 USD (low 7.00, high 12.00) · as of 12 Nov 2026
Low 7.00
Mean 9.00
High 12.00
Price 2.12
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Eledon Pharmaceuticals, Inc. Logo Eledon Pharmaceuticals, Inc. Analysis (ELDN)

United States Health Care Official Website Stock

Is Eledon Pharmaceuticals, Inc. a good investment? Eledon Pharmaceuticals, Inc. (ELDN) is currently trading at 2.12 USD. Market analysts have a consensus price target of 9.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Eledon Pharmaceuticals, Inc. is expected to release its next earnings report on March 18, 2027. The market consensus estimate for Forward EPS is -0.77.

Investor FAQ

Does Eledon Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Eledon Pharmaceuticals, Inc.?

Eledon Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 18, 2027. The company currently has a trailing EPS of -0.90.

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Exchange Ticker
NMS (United States) ELDN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 11, 2017 0.11
Oct. 5, 2020 0.06
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion